WO2021136488A1 - 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 - Google Patents
一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 Download PDFInfo
- Publication number
- WO2021136488A1 WO2021136488A1 PCT/CN2020/142037 CN2020142037W WO2021136488A1 WO 2021136488 A1 WO2021136488 A1 WO 2021136488A1 CN 2020142037 W CN2020142037 W CN 2020142037W WO 2021136488 A1 WO2021136488 A1 WO 2021136488A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- formula
- compound represented
- compound
- solvent
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, in particular to a crystal form of a compound of formula (I) and a preparation method thereof.
- TLRs Toll-like receptors
- TLR8 is a member of the subgroup of TLRs (TLRs 3, 7, 8 and 9) and is limited to the endosomal compartment of cells that specifically recognize non-self nucleic acids. TLR8 is mainly expressed in humans by monocytes, NK cells and myeloid dendritic cells (mDC). TLR8 agonists can cause the release of various pro-inflammatory cytokines, such as IL-6, IL-12, TNF- ⁇ and IFN- ⁇ .
- TLR8 plays an important role in the body's innate immunity and acquired immunity.
- TLR8 agonists can be used for the treatment of various immune-related diseases, such as ovarian cancer, melanoma, non-small cell lung cancer, hepatocellular carcinoma, basal cell carcinoma, and renal cell carcinoma , Myeloma, allergic rhinitis, asthma, chronic obstructive pneumonia (COPD), ulcerative colitis, liver fibrosis, HBV, Flaviviridae virus, HCV, HPV, RSV, SARS, HIV or epidemic Viral infection of colds, etc.
- various immune-related diseases such as ovarian cancer, melanoma, non-small cell lung cancer, hepatocellular carcinoma, basal cell carcinoma, and renal cell carcinoma , Myeloma, allergic rhinitis, asthma, chronic obstructive pneumonia (COPD), ulcerative colitis, liver fibrosis, HBV, Flaviviridae virus, HCV, HPV, RSV,
- TLR8 and TLR7 are highly homologous, TLR8 agonists are also TLR7 agonists in most cases. Therefore, dual agonists of TLR8 and TLR7 have been reported in many patents, such as WO2009111337, WO2011017611, WO2011068233, WO2011139348, WO2012066336, WO2013033345 and WO2017046112.
- TLR8 selective agonists mainly VentiRX’s VTX-2337 (WO2007024612) and Gilead’s GS-9688 (WO2016141092), but these two compounds still have a certain degree of activity on TLR7, and have a certain effect on Cyp and hERG. The selectivity is also poor. Therefore, it is still necessary to continue to develop safe and therapeutically more effective TLR8 agonists.
- WO2020007275 (application number: PCT/CN/2019/094310) relates to a compound represented by formula (I), the chemical name is (R)-2-((2-amino-7-(6-((4-methyl) Piperazin-1-yl)methyl)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexane-1-ol, this compound is a novel TLR8 Agonists have been improved in terms of clinical efficacy, indications, and safety, and their structure is as follows:
- the crystal structure of medicinal active ingredients often affects the chemical stability of the drug.
- the difference in crystallization conditions and storage conditions may lead to changes in the crystal structure of the compound, sometimes accompanied by the production of other crystalline forms.
- amorphous drug products have no regular crystal structure and often have other defects, such as poor product stability, finer crystallization, difficult filtration, easy agglomeration, and poor fluidity. Therefore, it is necessary to improve the properties of the above-mentioned products. We need in-depth research to find new crystal forms with higher crystal purity and good chemical stability.
- the purpose of the present disclosure is to provide a new crystal form of the compound represented by formula (I), which has good stability and can be better applied in clinics.
- One aspect of the present disclosure provides a crystal form A of the compound represented by formula (I), whose X-ray powder diffraction pattern at 2 ⁇ angles is 8.610, 9.740, 13.903, 15.313, 16.354, 17.675, 17.879, 19.184, 19.905, 20.901 There are characteristic peaks at, 21.365, 22.319 and 23.057,
- the present disclosure provides a crystal form A of the compound represented by formula (I), whose X-ray powder diffraction pattern at 2 ⁇ angles is 8.610, 9.740, 10.949, 13.314, 13.903, 15.313, 16.060, 16.354 There are characteristic peaks at, 16.794, 17.675, 17.879, 19.184, 19.905, 20.901, 21.365, 22.319, 23.057, 23.748, 24.430, 25.428, 26.576, 27.270, 27.863, 28.957, 29.842 and 31.506.
- the present disclosure provides a crystal form A of the compound represented by formula (I), and its X-ray powder diffraction pattern is shown in FIG. 2.
- the present disclosure further provides a method for preparing the above-mentioned crystal form A of the compound represented by formula (I), the method comprising:
- the solvent can be one or more of methanol, n-heptane, cyclohexane, n-hexane, petroleum ether, and n-propanol; or ,
- the compound represented by formula (I) is mixed with an appropriate amount of solvent, dissolved at elevated temperature, and crystallized at lowered temperature.
- the solvent may be ethyl acetate.
- One aspect of the present disclosure provides a crystal form B of the compound represented by formula (I), and its X-ray powder diffraction pattern at 2 ⁇ angles is 4.60, 8.77, 9.90, 13.86, 15.45, 16.44, 17.74, 18.03, 19.31, 19.91 There are characteristic peaks at, 21.07, 21.52, 22.48 and 23.22,
- the present disclosure provides a crystal form B of the compound represented by formula (I), and its X-ray powder diffraction pattern at 2 ⁇ angles is 4.60, 8.77, 9.20, 9.90, 11.17, 13.86, 14.51, 15.45 Available at, 16.44, 17.74, 18.03, 18.19, 18.51, 19.31, 19.91, 20.07, 21.07, 21.52, 22.48, 23.22, 24.00, 24.61, 25.64, 26.78, 27.43, 28.04, 29.31, 31.21, 32.09, 32.57, 33.23 and 34.01 Characteristic peaks.
- the present disclosure provides a crystal form B of the compound represented by formula (I), and its X-ray powder diffraction pattern is shown in FIG. 4.
- the present disclosure further provides a method for preparing the above-mentioned crystal form B of the compound represented by formula (I), the method comprising:
- the compound represented by formula (I) is mixed with an appropriate amount of solvent to volatilize and crystallize.
- the solvent can be water, isopropanol, ethyl acetate, acetonitrile, acetophenone, dichloromethane, N,N-dimethylformaldehyde One or more of amide and 1,2-dichloroethane; or,
- the compound represented by formula (I) is mixed with an appropriate amount of solvent, dissolved at elevated temperature, and crystallized at lowered temperature.
- the solvent may be isopropanol or dimethyl sulfoxide.
- the structure determination and crystal form study of the crystal form obtained in the present disclosure are carried out by X-ray powder diffraction pattern (XRPD) and differential scanning calorimetry (DSC).
- XRPD X-ray powder diffraction pattern
- DSC differential scanning calorimetry
- the mixed crystals of crystal form A and crystal form B can be prepared by using certain solvents.
- the compound represented by formula (I) and an appropriate amount of solvent such as acetone, isopropyl acetate, methyl Tert-butyl ether, 2-butanone, methyl isobutyl ketone, nitromethane, ethyl acetate/n-heptane, butyl acetate, p-xylene, propylene glycol monomethyl ether, isoamyl alcohol, water/ethanol , Water/acetone, ethyl acetate/ethanol, trichloromethane, etc.) mixed, volatilized and crystallized.
- solvents such as acetone, isopropyl acetate, methyl Tert-butyl ether, 2-butanone, methyl isobutyl ketone, nitromethane, ethyl acetate/n-heptane, butyl acetate, p-x
- the crystallization method of the crystal form in the present disclosure is conventional, such as volatilization crystallization, cooling crystallization or crystallization at room temperature.
- the starting material used in the method for preparing the crystal form of the present disclosure can be any form of the compound represented by formula (I), and the specific form includes, but is not limited to: amorphous, any crystal form, hydrate, solvate, and the like.
- the present disclosure further provides a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned crystal form A and/or crystal form B of the compound represented by formula (I), and one or more pharmaceutically acceptable carriers or excipients.
- the present disclosure further provides a pharmaceutical composition, which is prepared by mixing the above-mentioned crystal form A and/or crystal form B of the compound represented by formula (I) with one or more pharmaceutically acceptable carriers or excipients .
- the present disclosure further provides a method for preparing a pharmaceutical composition, which comprises combining the above-mentioned crystal form A and/or crystal form B of the compound represented by formula (I) with one or more pharmaceutically acceptable carriers or excipients Mixed steps.
- the present disclosure further provides the use of the crystal form A or crystal form B or the pharmaceutical composition of the compound represented by formula (I) described in the present disclosure in the preparation of a medicament for agonizing TLR8.
- the present disclosure further provides the use of the crystal form A or crystal form B or the pharmaceutical composition of the compound represented by formula (I) described in the present disclosure in the preparation of a medicament for the treatment of infection caused by a virus, and the virus is preferably form B One or more of hepatitis virus, hepatitis C virus, influenza virus, herpes virus and HIV.
- the present disclosure further provides the use of the crystal form A or crystal form B or the pharmaceutical composition of the compound represented by formula (I) described in the present disclosure in the preparation of drugs for regulating the immune system.
- the present disclosure further provides the use of the crystal form A or crystal form B or the pharmaceutical composition of the compound represented by the formula (I) described in the present disclosure in the preparation of a medicine for treating or preventing tumors.
- the “beating” mentioned in the present disclosure refers to a method of purifying substances with poor solubility in solvents but good solubility in solvents.
- the beating purification can remove color, change crystal form, or remove a small amount of impurities.
- the "X-ray powder diffraction pattern or XRPD" described in the present disclosure is a pattern obtained by using Cu-K ⁇ radiation in an X-ray powder diffractometer.
- the “differential scanning calorimetry or DSC” mentioned in the present disclosure refers to the measurement of the temperature difference and heat flow difference between the sample and the reference material during the temperature rise or constant temperature process of the sample to characterize all the physical changes and chemistry related to the thermal effect. Change, get the phase change information of the sample.
- the "2 ⁇ or 2 ⁇ angle" mentioned in the present disclosure refers to the diffraction angle, ⁇ is the Bragg angle, and the unit is ° or degree, and the error range of 2 ⁇ is ⁇ 0.3 or ⁇ 0.2 or ⁇ 0.1.
- interplanar spacing or interplanar spacing (d value) means that the spatial lattice selects three non-parallel unit vectors a, b, and c that connect two adjacent lattice points.
- the matrix is divided into juxtaposed parallelepiped units, called interplanar spacing.
- the spatial lattice is divided according to the determined parallelepiped unit lines to obtain a set of linear grids, called spatial lattices or lattices.
- Lattice and crystal lattice use geometric points and lines to reflect the periodicity of the crystal structure.
- the interplanar spacing that is, the distance between two adjacent parallel crystal planes
- the unit is Or angstrom.
- the crystal form A and crystal form B of the compound represented by formula (I) prepared by the present disclosure have high purity, good stability of the crystal form under the conditions of light, high temperature, and high humidity, small changes in HPLC purity, high physical and chemical stability, and more Conducive to the storage and use of raw materials.
- Figure 1 is the amorphous XRPD pattern of the compound represented by formula (I).
- Figure 2 is the XRPD pattern of the crystal form A of the compound represented by formula (I).
- Figure 3 is a DSC chart of the crystal form A of the compound represented by formula (I).
- Figure 4 is the XRPD pattern of the crystal form B of the compound represented by formula (I).
- Figure 5 is a DSC chart of the crystal form B of the compound represented by formula (I).
- Fig. 6 is an XRPD pattern of a mixed crystal of crystal form A and crystal form B of the compound represented by formula (I).
- Purge gas nitrogen.
- Heating rate 10.0°C/min.
- Purge gas nitrogen.
- Heating rate 10.0°C/min.
- Cu-K ⁇ 1 wavelength is The wavelength of Cu-K ⁇ 2 is Cu-K ⁇ wavelength is the weighted average of K ⁇ 1 and K ⁇ 2 ).
- Cu-K ⁇ 1 wavelength is The wavelength of Cu-K ⁇ 2 is Cu-K ⁇ wavelength is the weighted average of K ⁇ 1 and K ⁇ 2 ).
- the 2 ⁇ data with 2 decimal places is measured by the BRUKER D8 Focus X-ray powder diffractometer.
- reaction can be carried out in an argon atmosphere or a nitrogen atmosphere.
- the argon atmosphere or nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon with a volume of about 1L.
- the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon with a volume of about 1L.
- the pressure hydrogenation reaction uses Parr 3916EKX hydrogenator and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenator.
- the hydrogenation reaction is usually evacuated and filled with hydrogen, and the operation is repeated 3 times.
- the microwave reaction uses the CEM Discover-S 908860 microwave reactor.
- the solution refers to an aqueous solution.
- reaction temperature is room temperature, which is 20°C to 30°C.
- the monitoring of the reaction progress in the examples adopts thin layer chromatography (TLC), the developing solvent used in the reaction, the eluent system of column chromatography used in the purification of the compound, and the developing reagent system of thin layer chromatography include: A: Dichloromethane/methanol system, B: n-hexane/ethyl acetate system, C: petroleum ether/ethyl acetate system
- A Dichloromethane/methanol system
- B n-hexane/ethyl acetate system
- C petroleum ether/ethyl acetate system
- the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine and acetic acid can also be added Wait for alkaline or acidic reagents to adjust.
- Test Example 1 Determination of the agonistic activity of the compounds of the present disclosure on human TLR8 and TLR7
- HEK-Blue TM hTLR8 cell line (InvivoGen, hkb-hTLR8), or HEK-Blue TM hTLR7 cell line (InvivoGen, hkb-hTLR7),
- PBS Phosphate buffered saline
- HEK-Blue detection medium Take a bag of HEK-Blue detection dry powder, add 50ml of endotoxin-free water to dissolve it, then put it into the 37°C incubator, and filter aseptically after 10 minutes.
- the compound is first prepared into a 20 mM stock solution; then diluted with pure DMSO to a maximum concentration of 6 ⁇ 10 6 nM, and then diluted in a 3-fold gradient, a total of 10 points; the compound is diluted 20 times with the culture medium, and then 20 ⁇ l is added to each well. After the compound.
- HEK-Blue TM hTLR8 cells Take HEK-Blue TM hTLR8 cells, first remove the supernatant, add 2-5ml of pre-warmed PBS, put them in the incubator for 1-2 minutes, gently pipette the cells, trypan blue staining and counting. Resuspend the cells with HEK-Blue detection medium to adjust the concentration to 2.2 ⁇ 10 5 cells/ml, add 180 ⁇ l cells to the aforementioned 96-well cell culture plate to which 20 ⁇ l drugs have been added, and culture at 37° C. for 6-16 h.
- the wavelength is 620nm.
- the corresponding OD value can be obtained, and the EC 50 value of the drug can be calculated by Graphpad Prism.
- HEK-Blue detection medium Take a bag of HEK-Blue detection dry powder, add 50ml of endotoxin-free water to dissolve it, then put it into the 37°C incubator, and filter aseptically after 10 minutes.
- the compound was first prepared into a 20 mM stock solution; then diluted with pure DMSO to a maximum concentration of 6 ⁇ 10 6 nM, and then diluted by a 3-fold gradient for a total of 10 points.
- the compound prepared above is first diluted 20 times with culture medium, and then 20 ⁇ l of the diluted compound is added to each well.
- HEK-Blue TM hTLR7 cells Take HEK-Blue TM hTLR7 cells, first remove the supernatant, then add 2-5ml of pre-warmed PBS, put them in the incubator for 1-2 minutes, gently pipette the cells, trypan blue staining and counting. Resuspend the cells with HEK-Blue detection medium to adjust the concentration to 2.2 ⁇ 10 5 cells/ml, add 180 ⁇ l cells to the aforementioned 96-well cell culture plate to which 20 ⁇ l drugs have been added, and culture at 37° C. for 6-16 h.
- the wavelength is 620nm.
- the corresponding OD value can be obtained, and the EC 50 value of the drug can be calculated by Graphpad Prism.
- the activating effect of the compounds of the present disclosure on human TLR8 and TLR7 can be determined by the above test, and the measured EC 50 values are shown in Table 1-1.
- Table 1-1 EC 50 of the compounds of the present disclosure on human TLR8 and TLR7
- the compound of the present disclosure has a good activating effect on human TLR8, but has no activating effect on human TLR7, indicating that the compound of the present disclosure is selective for TLR8.
- Test Example 2 The inhibitory effect of the compound of the present disclosure on the enzyme activity of the metabolite site of human liver microsome CYP3A4 midazolam
- PBS Phosphate buffered saline
- CYP probe substrate (15 ⁇ M midazolam, SIGMA UC429) and positive control inhibitor (ketoconazole, SIGMA K1003).
- the value is calculated by Graphpad Prism to obtain the IC 50 value of the drug to the metabolite site of CYP3A4 midazolam, shown in Table 1-2.
- Table 1-2 IC 50 values of the compounds of the present disclosure on the metabolism site of CYP3A4 midazolam
- the compound of the present disclosure has no inhibitory effect on the midazolam metabolism site of human liver microsomes CYP3A4, and shows better safety, suggesting that there will be no metabolic drug interaction based on the midazolam metabolism site of CYP3A4 metabolism. effect.
- Test Example 3 The inhibitory effect of the compound of the present disclosure on the enzyme activity of human liver microsomes CYP2D6
- the enzyme activity of the compounds of the present disclosure on human liver microsomes CYP2D6 was determined by the following experimental method:
- PBS Phosphate buffered saline
- CYP probe substrate (20 ⁇ M dextromethorphan, SIGMA Q0750) and positive control inhibitor (quinidine, SIGMA D9684).
- Table 1-3 IC 50 values of the compounds of the present disclosure on the metabolic sites of CYP2D6
- the compound of the present disclosure has weak inhibitory effect on the enzyme activity of human liver microsomes CYP2D6, and shows better safety, suggesting that there will be no metabolic drug interactions based on CYP2D6.
- Test Example 4 The inhibitory effect of the compound of the present disclosure on the enzyme activity of human liver microsome CYP3A4 testosterone metabolism site
- the enzymatic activity of the compounds of the present disclosure on the testosterone metabolism site of human liver microsome CYP3A4 was determined by the following experimental method:
- PBS Phosphate buffered saline
- CYP probe substrate testosterone/100 ⁇ M, SIGMA K1003
- positive control inhibitor ketoconazole, Dr. Ehrenstorfer GmbH, C17322500
- the values are calculated by Graphpad Prism to obtain the IC 50 value of the drug to the CYP3A4 testosterone metabolism site, shown in Table 1-4.
- Table 1-4 IC 50 values of the compounds of the present disclosure on CYP3A4 testosterone metabolism sites
- the compound of the present disclosure has no inhibitory effect on the testosterone metabolism site of human liver microsome CYP3A4, and shows better safety, suggesting that there will be no metabolic drug interaction based on the testosterone metabolism site of CYP3A4.
- Test Example 5 Determination of the ability of the compounds in the present disclosure to stimulate peripheral blood mononuclear cells (PBMC) to secrete IL12 and IFN ⁇
- PHERAStar multifunctional microplate reader BMG, PHERAStar.
- the compound was diluted with pure DMSO, the highest concentration was 5 mM, and it was diluted 4-fold with a total of 9 points. Then take 4 ⁇ l of the compound and add it to 196 ⁇ l of RMPI 1640 medium containing 10% FBS, and mix well. Take 50 ⁇ l to a new 96-well cell culture plate.
- All reagents are equilibrated to room temperature, take a 250ml culture flask, add 60ml blood and equal volume of PBS+2% FBS to it, gently pipette to mix and dilute. Take 50ml PBMC separation tube SepMateTM-50, add 15ml lymphocyte separation fluid Ficoll-Paque PREMIUM, and then add 30ml diluted blood. Centrifuge at 1200g for 10 minutes at room temperature. Take the supernatant and centrifuge at 300g for 8 minutes.
- RMPI 1640 medium containing 10% FBS Resuspend and count in RMPI 1640 medium containing 10% FBS, adjust the number of PBMCs to 3.33 ⁇ 10 6 cells/ml, and transfer 150 ⁇ l to the cell culture plate to which the compound has been added, 37°C, 5.0% CO2 in an incubator Cultivate for 24h. Put the cell culture plate in a centrifuge, centrifuge at 1200 rpm for 10 minutes at room temperature, and take out 150 ⁇ l of supernatant from each well.
- the maximum concentration of the standard is 2000pg/ml, with a total of 8 points of double-gradient dilution.
- the sample to be tested is diluted 20 times. Then 100 ⁇ l/well was added to the pre-coated plate. Incubate at 37°C for 90 min. .Wash the plate and add 100 ⁇ l/well of antibioticized antibody. Incubate at 37°C for 60 min. Wash the plate and add 100 ⁇ l/well of HRP binding enzyme. Incubate at 37°C for 30 minutes and wash the plate; add TMB and incubate at room temperature for 5 minutes. Finally, stop solution was added to stop the reaction, and the absorbance value at 450nm was read by the microplate reader.
- Table 1-5 The compounds of the present disclosure stimulate PBMC to secrete IL12 and IFN ⁇ MEC
- Fully automatic patch clamp was used to test the blocking effect of the compounds of the present disclosure on hERG potassium currents on stable cell lines transfected with hERG potassium channels.
- the HEK293-hERG stable cell line was passaged in MEM/EBSS medium (10% FBS, 400 ⁇ g/ml G418, 1% MEM non-essential amino acid solution (100 ⁇ ), 1% sodium pyruvate solution) at a density of 1:4 Cultivate, and perform fully automatic patch clamp experiments within 48-72 hours of incubation.
- MEM/EBSS medium 10% FBS, 400 ⁇ g/ml G418, 1% MEM non-essential amino acid solution (100 ⁇ ), 1% sodium pyruvate solution
- the cells were digested with 0.25% trypsin on the day of the experiment, the cells were collected by centrifugation , and resuspended in extracellular fluid (140mM NaCl, 4mM KCl, 1mM MgCl 2 , 2mM CaCl 2 , 5mM D glucose monohydrate, 10mM Hepes, pH7.4, 298mOsmol)
- extracellular fluid 140mM NaCl, 4mM KCl, 1mM MgCl 2 , 2mM CaCl 2 , 5mM D glucose monohydrate, 10mM Hepes, pH7.4, 298mOsmol
- the cells are made into a cell suspension.
- the cell suspension is placed on the cell bank of the Patchliner instrument.
- the Patchliner instrument uses a negative pressure controller to add cells to the chip (NPC-16), and the negative pressure attracts single cells to the small holes of the chip.
- the instrument When the whole-cell mode is formed, the instrument will obtain the hERG current according to the set hERG current and voltage program, and then the instrument will automatically change from low concentration to high concentration for compound perfusion.
- the data analysis software provided by HEAK Patchmaster, HEAK EPC10 Patch Clamp Amplifier (Nanion) and Pathlinersoftware and Pathcontrol HTsoftware were used to analyze the currents at each concentration of the compound and the blank control current.
- Table 1-6 IC of the present disclosure compound hERG potassium current blocking effect of 50
- the compound of the present disclosure has a weak inhibitory effect on hERG and can reduce the side effects caused by the hERG pathway.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
实施例编号 | IC 50(μM) |
1 | >30 |
实施例编号 | IC 50(μM) |
1 | >30 |
实施例编号 | IC 50(μM) |
1 | >30 |
实施例编号 | IL12 MEC(nM) | IFNγMEC(nM) |
1 | 41 | - |
实施例编号 | IC 50(μM) |
1 | 26 |
Claims (16)
- 根据权利要求1所述的式(I)所示化合物的A晶型,其X-射线粉末衍射图谱在2θ角为8.610、9.740、10.949、13.314、13.903、15.313、16.060、16.354、16.794、17.675、17.879、19.184、19.905、20.901、21.365、22.319、23.057、23.748、24.430、25.428、26.576、27.270、27.863、28.957、29.842和31.506处有特征峰。
- 根据权利要求1所述的式(I)所示化合物的A晶型,其X-射线粉末衍射图谱如图2所示。
- 根据权利要求4所述的式(I)所示化合物的B晶型,其X-射线粉末衍射图谱在2θ角为4.60、8.77、9.20、9.90、11.17、13.86、14.51、15.45、16.44、17.74、18.03、18.19、18.51、19.31、19.91、20.07、21.07、21.52、22.48、23.22、24.00、24.61、25.64、26.78、27.43、28.04、29.31、31.21、32.09、32.57、33.23和34.01处有特征峰。
- 根据权利要求4所述的式(I)所示化合物的B晶型,其X-射线粉末衍射图谱如图4 所示。
- 根据权利要求1-6任意一项所述的式(I)所示化合物的晶型,其中所述2θ角的误差范围为±0.2。
- 一种制备如权利要求1-3任意一项所述的式(I)所示化合物的A晶型的方法,所述方法包括:将式(I)所示化合物与适量的溶剂混合,挥发结晶,所述溶剂选自甲醇、正庚烷、环己烷、正己烷、石油醚和正丙醇中的一种或多种;或将式(I)所示化合物与适量的溶剂混合,升温溶解,降温结晶,所述溶剂为乙酸乙酯。
- 一种制备如权利要求4-6任意一项所述的式(I)所示化合物的B晶型的方法,所述方法包括:将式(I)所示化合物与适量的溶剂混合,挥发结晶,所述溶剂选自水、异丙醇、乙酸乙酯、乙腈、苯乙酮、二氯甲烷、N,N-二甲基甲酰胺和1,2-二氯乙烷中的一种或多种;或将式(I)所示化合物与适量的溶剂混合,升温溶解,降温结晶,所述溶剂选自异丙醇或二甲亚砜。
- 一种药物组合物,其包含如权利要求1-3任意一项所述的式(I)所示化合物的A晶型和/或如权利要求4-6任意一项所述的式(I)所示化合物的B晶型,以及一种或多种药学上可接受的载体或赋形剂。
- 一种药物组合物,其通过如权利要求1-3任意一项所述的式(I)所示化合物的A晶型和/或如权利要求4-6任意一项所述的式(I)所示化合物的B晶型与一种或多种药学上可接受的载体或赋形剂混合制备得到。
- 一种如权利要求1-7任意一项所述的式(I)所示化合物的A晶型或B晶型或权利要求10、11所述的药物组合物在制备用于激动TLR8的药物中的用途。
- 一种如权利要求1-7任意一项所述的式(I)所示化合物的A晶型或B晶型或权利要求10、11所述的药物组合物在制备用于治疗由病毒引起的感染的药物中的用途,所述病毒优选乙型肝炎病毒、丙型肝炎病毒、流感病毒、疱疹病毒和艾滋病毒中的一种或多种。
- 一种如权利要求1-7任意一项所述的式(I)所示化合物的A晶型或B晶型或权利要求10、11所述的药物组合物在制备用于调节免疫系统的药物中的用途。
- 一种如权利要求1-7任意一项所述的式(I)所示化合物的A晶型或B晶型或权利要求10、11所述的药物组合物在制备用于治疗或预防肿瘤的药物中的用途。
- 一种制备如权利要求10或11所述的药物组合物的方法,其包括将式(I)所示化合物的A晶型和/或B晶型与一种或多种药学上可接受的载体或赋形剂混合的步骤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020416484A AU2020416484A1 (en) | 2020-01-02 | 2020-12-31 | Crystal form of pyridopyrimidine derivative and preparation method thereof |
MX2022008286A MX2022008286A (es) | 2020-01-02 | 2020-12-31 | Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma. |
CN202080091758.4A CN114929232B (zh) | 2020-01-02 | 2020-12-31 | 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 |
JP2022540974A JP2023509175A (ja) | 2020-01-02 | 2020-12-31 | ピリドピリミジン系誘導体の結晶形及びその調製方法 |
EP20909539.7A EP4085914A4 (en) | 2020-01-02 | 2020-12-31 | CRYSTALLINE FORM OF A PYRIDOPYRIMIDI DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF |
CA3163386A CA3163386A1 (en) | 2020-01-02 | 2020-12-31 | Crystal form of pyridopyrimidine derivative and preparation method thereof |
US17/757,946 US20230058425A1 (en) | 2020-01-02 | 2020-12-31 | Crystal form of pyridopyrimidine derivative and preparation method thereof |
KR1020227026482A KR20220123437A (ko) | 2020-01-02 | 2020-12-31 | 피리도피리미딘 유도체의 결정형 및 이의 제조 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010002822.9 | 2020-01-02 | ||
CN202010002822 | 2020-01-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021136488A1 true WO2021136488A1 (zh) | 2021-07-08 |
Family
ID=76686512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/142037 WO2021136488A1 (zh) | 2020-01-02 | 2020-12-31 | 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230058425A1 (zh) |
EP (1) | EP4085914A4 (zh) |
JP (1) | JP2023509175A (zh) |
KR (1) | KR20220123437A (zh) |
CN (1) | CN114929232B (zh) |
AU (1) | AU2020416484A1 (zh) |
CA (1) | CA3163386A1 (zh) |
MX (1) | MX2022008286A (zh) |
TW (1) | TW202128692A (zh) |
WO (1) | WO2021136488A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022184113A1 (zh) * | 2021-03-03 | 2022-09-09 | 苏州盛迪亚生物医药有限公司 | 一种包含吡啶并嘧啶类衍生物的药物组合物及其制备方法 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026052A1 (en) | 2000-09-26 | 2002-04-04 | Unilever N.V. | Composition comprising a fat phase, vegetable matter and salt |
WO2007024612A2 (en) | 2005-08-19 | 2007-03-01 | Array Biopharma Inc. | 8-substituted benzoazepines as toll-like receptor modulators |
WO2009111337A1 (en) | 2008-03-03 | 2009-09-11 | Irm Llc | Compounds and compositions as tlr activity modulators |
WO2011017611A1 (en) | 2009-08-07 | 2011-02-10 | Glaxosmithkline Biologicals Sa | Lipidated oxoadenine derivatives |
WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
WO2011139348A2 (en) | 2010-04-30 | 2011-11-10 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2013033345A1 (en) | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
WO2014022728A1 (en) | 2012-08-02 | 2014-02-06 | Endo Pharmaceuticals, Inc | Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer |
WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
WO2017046112A1 (en) | 2015-09-17 | 2017-03-23 | F. Hoffmann-La Roche Ag | Sulfinylphenyl or sulfonimidoylphenyl benzazepines |
WO2017048727A1 (en) * | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
WO2018045150A1 (en) * | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
WO2019166532A1 (en) * | 2018-03-01 | 2019-09-06 | Janssen Sciences Ireland Unlimited Company | 2,4-diaminoquinazoline derivatives and medical uses thereof |
WO2020007275A1 (zh) | 2018-07-03 | 2020-01-09 | 江苏恒瑞医药股份有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012058671A1 (en) * | 2010-10-31 | 2012-05-03 | Endo Pharmaceuticals Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
CN110526918B (zh) * | 2018-05-25 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种吡唑并杂芳基类衍生物的晶型及制备方法 |
-
2020
- 2020-12-31 US US17/757,946 patent/US20230058425A1/en active Pending
- 2020-12-31 MX MX2022008286A patent/MX2022008286A/es unknown
- 2020-12-31 CN CN202080091758.4A patent/CN114929232B/zh active Active
- 2020-12-31 WO PCT/CN2020/142037 patent/WO2021136488A1/zh unknown
- 2020-12-31 TW TW109147161A patent/TW202128692A/zh unknown
- 2020-12-31 CA CA3163386A patent/CA3163386A1/en active Pending
- 2020-12-31 EP EP20909539.7A patent/EP4085914A4/en active Pending
- 2020-12-31 AU AU2020416484A patent/AU2020416484A1/en active Pending
- 2020-12-31 JP JP2022540974A patent/JP2023509175A/ja active Pending
- 2020-12-31 KR KR1020227026482A patent/KR20220123437A/ko unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026052A1 (en) | 2000-09-26 | 2002-04-04 | Unilever N.V. | Composition comprising a fat phase, vegetable matter and salt |
WO2007024612A2 (en) | 2005-08-19 | 2007-03-01 | Array Biopharma Inc. | 8-substituted benzoazepines as toll-like receptor modulators |
WO2009111337A1 (en) | 2008-03-03 | 2009-09-11 | Irm Llc | Compounds and compositions as tlr activity modulators |
WO2011017611A1 (en) | 2009-08-07 | 2011-02-10 | Glaxosmithkline Biologicals Sa | Lipidated oxoadenine derivatives |
WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
WO2011139348A2 (en) | 2010-04-30 | 2011-11-10 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2013033345A1 (en) | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
WO2014022728A1 (en) | 2012-08-02 | 2014-02-06 | Endo Pharmaceuticals, Inc | Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer |
WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
CN107108615A (zh) * | 2015-03-04 | 2017-08-29 | 吉利德科学公司 | Toll样受体调节性4,6‑二氨基‑吡啶并[3,2‑D]嘧啶化合物 |
WO2017048727A1 (en) * | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
WO2017046112A1 (en) | 2015-09-17 | 2017-03-23 | F. Hoffmann-La Roche Ag | Sulfinylphenyl or sulfonimidoylphenyl benzazepines |
WO2018045150A1 (en) * | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
WO2019166532A1 (en) * | 2018-03-01 | 2019-09-06 | Janssen Sciences Ireland Unlimited Company | 2,4-diaminoquinazoline derivatives and medical uses thereof |
WO2020007275A1 (zh) | 2018-07-03 | 2020-01-09 | 江苏恒瑞医药股份有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
Non-Patent Citations (1)
Title |
---|
MAHLA, R S. ET AL., FRONT IMMUNOL., vol. 4, 2013, pages 248 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022184113A1 (zh) * | 2021-03-03 | 2022-09-09 | 苏州盛迪亚生物医药有限公司 | 一种包含吡啶并嘧啶类衍生物的药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2020416484A1 (en) | 2022-08-25 |
KR20220123437A (ko) | 2022-09-06 |
CN114929232B (zh) | 2023-06-16 |
US20230058425A1 (en) | 2023-02-23 |
TW202128692A (zh) | 2021-08-01 |
EP4085914A4 (en) | 2023-06-21 |
CN114929232A (zh) | 2022-08-19 |
JP2023509175A (ja) | 2023-03-07 |
CA3163386A1 (en) | 2021-07-08 |
MX2022008286A (es) | 2022-08-08 |
EP4085914A1 (en) | 2022-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20230117573A (ko) | Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법 | |
JP2023500395A (ja) | Pd-1/pd-l1阻害剤の塩及び結晶形態 | |
NZ567433A (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
AU2017282903B2 (en) | Crystals of aniline pyrimidine compound serving as EGFR inhibitor | |
TWI705060B (zh) | 一種mek激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法 | |
WO2021136488A1 (zh) | 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法 | |
WO2007039580A1 (en) | Imidazolyl-substituted benzophenone compounds | |
WO2007039578A1 (en) | Imidazolyl-substituted azabenzophenone compounds | |
CN110526918B (zh) | 一种吡唑并杂芳基类衍生物的晶型及制备方法 | |
JP7472138B2 (ja) | Syk阻害剤の塩及びその結晶形 | |
TWI704916B (zh) | 一種吡唑并雜芳基類衍生物鹽酸鹽的晶型及製備方法 | |
CN110194741B (zh) | 4-苯甲酰哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其制备方法和应用 | |
CN113461661B (zh) | 6-(吡啶-3-基)喹唑啉-4(3h)-酮类衍生物及其制备和应用 | |
WO2021185312A1 (zh) | 一种tlr8激动剂晶型 | |
WO2024109871A1 (zh) | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 | |
CN110272388B (zh) | 4-二硫代甲酸哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其合成方法和应用 | |
WO2022247942A1 (zh) | 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 | |
CN111217748B (zh) | 一种螺环二氢异喹啉甲酰胺类衍生物的晶型及其制备方法 | |
WO2023246858A1 (zh) | 一种硼酸酯衍生物的可药用盐、其结晶形式及用途 | |
TWI788444B (zh) | Fgfr4抑制劑晶型及其製備方法 | |
WO2023093861A1 (zh) | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 | |
WO2007039581A1 (en) | Imidazolyl-substituted diazabenzophenone compounds | |
TW202421139A (zh) | 一種含氮雜環類化合物的可藥用鹽、晶型及製備方法 | |
CN110526917A (zh) | 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法 | |
TW202408510A (zh) | Cdk抑制劑及其磷酸鹽的多晶型、其製備方法、包含其的醫藥組合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20909539 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3163386 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022540974 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227026482 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020909539 Country of ref document: EP Effective date: 20220802 |
|
ENP | Entry into the national phase |
Ref document number: 2020416484 Country of ref document: AU Date of ref document: 20201231 Kind code of ref document: A |